We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Biohaven in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now expects that ...

In this article, we will take a detailed look at 12 Stocks with Heavy Insider Buying in 2025.

Highlights,Institutional firms have modified their holdings in Biohaven Ltd., contributing to shifts in stock ...

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Royal Bank of Canada restated their outperform rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report published ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 ...

Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.